Fig 1: Effects of fludrocortisone and ATII on Epo protein expression in the kidney and liver. (a) Effects of fludrocortisone on Epo production in the kidney. Fludrocortisone increased deglycosylated Epo protein expression at 2 and 4 h after the injection. The levels returned to basal values after 6 h. (b) ATII dose-dependently increased deglycosylated Epo protein expression in the renal cortex and outer medulla. The effects were larger in the renal cortex than in the renal outer medulla. (c) ATII increased deglycosylated Epo production in the renal cortex by 1.6- and 3.4-fold by 1 and 10 mg/kg, respectively. (d) In contrast, deglycosylated Epo production was not observed in control and ATII-injected livers. Recombinant rat Epo is shown as the control in Figure 3c. Glycosylated Epo and deglycosylated rat Epo were used in lane 1. Glycosylated Epo and deglycosylated Epo were used in lanes 11 and 12, respectively. * p < 0.05, ** p < 0.01 by a non-parametric analysis using the Kruskal–Wallis test and multiple comparisons by the Shirley–Williams’ test.
Fig 2: Detection of urinary Epo and ESAs by Western blotting with deglycosylation. Urinary Epo and ESAs were investigated by Western blotting. Endogenous urinary Epo (②) was smaller than ESAs (③-⑥). The bands for endogenous Epo and ESAs, except epoetin β pegol, were shifted to 22 kDa by deglycosylation. The band of PEG-bound epoetin β pegol was slightly reduced in size by deglycosylation. The sizes of endogenous Epo and ESAs before and after deglycosylaton by Western blotting and by LC/MS analysis (Table 1) were summarized in the Table. Glycosylated rhEpo (①), urine Epo (②) and ESAs (③-⑥) are indicated by blue arrows. The amount of samples are as follows: urine Epo (33.3 mIU); epoetin α and β (16.7 mIU); darbepoietin (111 pg); and epoetin β pegol 231 pg rhEpo, recombinant human Epo, Endo Epo, endogenous Epo. ① rhEpo, ② human urine Epo, ③ epoetin α, ④ epoetin β, ⑤ darbepoetin α, and ⑥ epoetin β pegol.
Fig 3: hCAR downregulates EPO expression through suppression of HNF4α.A, RT–PCR was used to analyze expression of hCAR, EPO, HNF4α, and HIF1β in HepG2-hCAR and Hep3B-hCAR cells 72 h after treatment with vehicle control or Dox (1 μg/ml) as detailed in the “Experimental procedures” section. B, the protein levels of HNF4α were analyzed by immunoblotting in HepG2-hCAR, Hep3B-hCAR, as well as normal HepG2 and Hep3B cells treated with vehicle control or Dox for 72 h. Relative blot densitometry was quantified using ImageJ from three separately prepared cell experiments and normalized to the density of the loading control. C, knockdown of HNF4α expression in HepG2 and Hep3B cells via lentivirus shRNA targeting different regions of HNF4α (shHNF4α-1 and shHNF4α-2) resulted in downregulation of EPO expression in these cells. D, overexpression of HNF4α partially rescues hCAR-mediated downregulation of EPO expression in HepG2-hCAR and Hep3B-hCAR stable cell lines. E, EMSA was performed to detect interaction between the EPO–DR2 motif and nuclear extract samples isolated from HepG2-hCAR and Hep3B-hCAR cells treated with vehicle control or Dox for 72 h. HNF4α antibody was used for measuring specific supershift of the HNF4α/DR2 band. 1: NE of HepG2-hCAR-control; 2: NE of HepG2-hCAR-Dox; 3: NE of Hep3B-hCAR-control; and 4: NE of Hep3B-hCAR-Dox. F, HEK293T cells were transfected with EPO-3′UTR-enhancer reporter construct in the presence of HNF4α and/or hCAR expression vectors as indicated, and luciferase activities were determined 48 h after transfection. Three independent measures from each group were analyzed and expressed as mean ± SD. ∗p < 0.05 and ∗∗p < 0.01. Dox, doxycycline; DR2, direct repeat 2; EPO, erythropoietin; hCAR, human constitutive androstane receptor; HEK293T, human embryonic kidney 293T cell line; HIF1β, hypoxia-inducible factor 1β; HNF4α, hepatocyte nuclear factor 4 alpha.
Fig 4: RNA-Seq analysis identifies EPO as a novel hCAR target gene. The total RNA from HepG2-hCAR was prepared 72 h after Dox (1 μg/ml) or vehicle control treatment for RNA-Seq analysis as detailed under the “Experimental procedures” section. A, the volcano plot of RNA-Seq data showed 374 upregulated and 348 downregulated genes in HepG2-hCAR cells after hCAR induction. B, heatmaps illustrate 10 selected upregulated and downregulated genes with high fold changes in HepG2-hCAR cells treated with Dox or vehicle control. RT–PCR validation of RNA-Seq analysis results for the 10 upregulated and 10 downregulated genes in HepG2-hCAR (C), Hep3B-hCAR (D), HepaRG WT and hCAR-KO cells (E), respectively. Data were collected from three independent experiments and expressed as mean ± SD in C–E. ∗p < 0.05 and ∗∗p < 0.01. Dox, doxycycline; EPO, erythropoietin; hCAR, human constitutive androstane receptor; ND, not detected.
Fig 5: Immunohistochemical study of the effects of ATII on Epo production by the kidney. Under basal conditions, Epo staining was found from the proximal tubules to the collecting ducts (proximal tubules < thick ascending limbs < collecting ducts) (1-a–c). ATII increased Epo production in MAL, CCD, and OMCD (3~4-a–c), particularly in the type A intercalated cells, after 4–6 h (brown cells in 3~4-a–c). The renal outer medulla is shown at a different magnification. The numbers 1, 2, 3, and 4 show 0, 2, 4, and 6 h after the injection of ATII, respectively.
Supplier Page from BioLegend for Recombinant Human Erythropoietin (EPO) (carrier-free)